AC Immune announces publication of results on ACI-35.030 in eBioMedicine

AC Immune (ACIU) announced the peer-reviewed publication in eBioMedicine of results from the completed Phase 1b/2a trial of active immunotherapy ACI-35.030’s partnered with Janssen Pharmaceuticals, a Johnson & Johnson (JNJ) company. ACI-35.030 generated a rapid, robust and durable polyclonal response against pathological forms of Tau including phosphorylated Tau and brain-derived Tau. There were no clinically relevant safety or tolerability observations for either ACI-35.030 or JACI-35.054. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “These data show that ACI-35.030 was well tolerated at all tested doses and induced a rapid and sustained response against pathological Tau, while requiring less frequent dosing to maintain titers as compared to monoclonal antibodies. Safety and rapid, durable responses are key advantages of active immunotherapies, which make them particularly well suited to the long-term treatment needed to achieve precision prevention. ACI-35.030 is continuing to progress according to plan in the Phase 2b ReTain trial, being conducted by our development partner Johnson & Johnson.”